



PERSONAL INFORMATION

DÉSIRÉE DEANDREIS – CURRICULUM VITAE

Date of birth: 09.26.1977 Bergamo (Italy);

Telephone: +39 011 6335024

E-mail: desiree.deandreis@unito.it / deandreisde@gmail.com

CURRENT POSITIONS

Director of Nuclear Medicine Division (November 2019 - to present)

AOU Città della salute e della Scienza di Torino

Corso Dogliotti, 14

10126 Torino, Italy

Director of Nuclear Medicine Residency Program (November 2019 - to present)

Associate Professor of Nuclear Medicine (October 2016 - to present)

Department of Medical Sciences

University of Turin

Division of Nuclear Medicine

AOU Città della Salute e della Scienza

Corso AM Dogliotti 14

10126 Torino, Italy

Member and delegate for Italy of UEMS/EBNM/EANM (Section of Nuclear Medicine of the European Union of Medical Specialists (UEMS) and European Board of Nuclear Medicine (EBNM)).

Member of EANM Thyroid Committee and Representative for ESMIT (January 2021-to present)

Member of COST (European Cooperation in Science and technology) (MAY 2020-to present)

MEDICAL BOARD CERTIFICATIONS

Ordre des Médecins Val de Marne, France : 15291, RPPS 10004039540;

Ordine dei Medici Chirurghi et Odontoiatri, Torino, Italia: 20049 19.12.2003

MEMBERSHIPS

Associazione Italiana di Medicina Nucleare (AIMN)

European Association of Nuclear Medicine (EANM)

LANGUAGES

Italian: Mother language;

French: Fluent written and spoken;

English: Fluent written and spoken.



EDUCATION and QUALIFICATIONS

October 2018

Italian National Scientific License for a position of Full Professor in Medical Imaging, Radiotherapy and Neuroradiology, by Italian Ministry of University and Research.

Abilitazione Scientifica Nazionale Settore «Diagnostica per Immagini, Radioterapia e Neuroradiologia», MIUR, Bando 2016-2018

October 2016

Position of Associate Professor of Nuclear Medicine, Department of Medical Sciences, University of Turin, Italy

November 2012-October 2016

Assistant Professor/Physician in Nuclear Medicine

Division of Nuclear Medicine and Endocrine Oncology (Prof. M Schlumberger)
Gustave Roussy, Villejuif, France

2012

Italian Scientific Licence for a position of Associate Professor in Medical Imaging, Radiotherapy and Neuroradiology, by Italian Ministry for University and Research.

Abilitazione Scientifica Nazionale Settore «Diagnostica per Immagini, Radioterapia e Neuroradiologia», MIUR, Bando 2012 (DD n°222/2012)

2010-2011

Visiting Investigator/Fellowship Research Program on Thyroid Cancer

Department of Nuclear Medicine and Endocrinology (Dr S. Larson, Dr M. Tuttle)
Memorial Sloan-Kettering Cancer Centre, New York
Research Grant by Fondation de France (www.fdf.org n° 2010-12521)

2008-2010

Fellowship in Nuclear Medicine and Endocrine Oncology

Service of Nuclear Medicine and Endocrine Oncology (Pr M. Schlumberger)
Gustave Roussy (GR), Villejuif, France;

2007-2008

European Master Degree in Clinical Oncology Research (DUERCC), Gustave Roussy

Academic Degree in Clinical Oncology, Paris XI University

Research project: "In vivo (FDG-PET and 131I) and in vitro characterisation of metastatic thyroid cancer". Tutor: Pr Martin Schlumberger (Gustave Roussy)

December 2007

Post-graduate Degree in Nuclear Medicine, Turin University (Italy)

Title: "FDG-PET/CT in the pre-surgical characterization of thyroid follicular neoplasms: preliminary results." Tutor: Pr M. Schlumberger (Gustave Roussy) Director: Pr G. Bisi (University of Turin)



2003-2007

Medical Specialty training in Nuclear Medicine

2006-2007: PET/CT and Radiometabolic treatment of thyroid cancer and Endocrine Tumors,

Division of Nuclear Medicine and Endocrine Cancer, Gustave Roussy, France;

2003-2006: Pediatric Nuclear Medicine, Bone disease, Nuclear Nephrology, Nuclear Cardiology; Sentinel Lymphnode for breast cancer, Melanoma, Head and neck tumors.

Department of Medical Sciences, University of Turin, Italy;

2003

Research Project supported by Piedmont Region, Turin, Italy;

Title: «Semi-quantitative evaluation of malignancy marker of thyroid cancer Galectine-3 in needle fine aspiration biopsy specimen and in serum: easy method for the early detection of Thyroid Cancer». *Tutor:* Pr F. Orlandi, University of Turin

April 2003

Degree in Medicine and Surgery, School of Medicine, University of Turin, Italy

Title: "Role of Galectin-3 immunodetection in the cytological diagnosis of thyroid cystic papillary carcinoma"

Tutor: Pr F. Orlandi, Pr M. Papotti, University of Turin

2001-2003

Internship in Endocrinology

Department of Internal Medicine and Endocrinology

S. Luigi Gonzaga Hospital, University of Turin, Italy

PROFESSIONAL SKILLS

Theragnostic and radio-ligand therapy:

Clinical Practice in Thyroid Cancer and Neuroendocrine Tumors

Radioactive iodine (¹³¹I)

Radio-ligand therapy

¹³¹I-MIBG

Samarium-153 and Radium-223;

Selective Internal Radiation Therapy (SIRT)

Dosimetry

Functional Imaging:

PET/CT (18F-FDG, 18F-DOPA, 18F choline, 18FNa, 68Ga-PSMA and DOTATOC)

SPECT/CT in Endocrinology (Tc99m and 123I scintigraphy, Tc99m SestaMIBI scintigraphy) and Bone Metabolism

Radiomics in Functional Imaging

PET/CT Reviewer for Clinical Trials

Member of Study Groups:

-January 2018 to present: Regional Study group (Oncological Network Piemonte e Val d'Aosta) for Diagnostic Imaging in Oncology. Referent for Nuclear Medicine



UNIVERSITÀ DEGLI STUDI DI TORINO

- March 2017 to present: Regional Study group (Oncological Network Piemonte e Val d'Aosta) for Thyroid Tumors and Neuroendocrine Tumors. **Referent for Radiometabolic treatment group.**
- October 2016 to present: **Member of Multidisciplinary team for Thyroid Cancer**, Neuroendocrine Tumors and Prostate Cancer, AOU Città della Salute e delle Scienza.
- 2011-2016: **Member of Multidisciplinary team for Thyroid Cancer**, Neuroendocrine Tumors and Prostate Cancer (Gustave Roussy, France)

Member of International Network (Gustave Roussy, France) (2011-2016)

- TUTHYREF (French National Network for Refractory Thyroid Tumors)
- RENATEN (French National Network for Neuroendocrine tumors)

OTHER EXPERTIZES:

Head of Research Laboratory for Radiomic in PET imaging

Department of Medical Sciences- Division of Nuclear Medicine
University of Turin

[www.dsm.unito.it/do/home.pl/View?doc=/gruppi di ricerca/Medicina Nucleare/Medicina Nucleare.html](http://www.dsm.unito.it/do/home.pl/View?doc=/gruppi%20di%20ricerca/Medicina%20Nucleare/Medicina%20Nucleare.html).

TEACHING EXPERIENCE

2019-to present: Member and teacher at Doctoral School in Life and Health Sciences, PhD Program in Medical Physiopathology.

Topic: Targets for Functional imaging in Medicine.

Tutor for the following projects:

2019: "Clinical impact of Dosimetry in nuclear medicine Therapy" (PhD student M. Finessi)

2019-ongoing: "Radiomics in Nuclear Medicine and hybrid imaging for heterogeneity of solid tumours: diagnostic and prognostic potential" (PhD student V.Liberini).

Since 2016-to present:

University of Turin-**School of Medicine** (Medical Imaging courses)

University of Turin-**Biotechnology** (In vivo imaging: PET, SPECT and CT)

University of Turin-**School of Radiology Technicians** (Nuclear Medicine)

University of Turin- **Nuclear Medicine Residency Program**

University of Turin-**Master in diagnostic and Interventional Neck Ultrasound**

2012-2016:

Masterclass in Oncology. Ecole des Sciences du Cancer, Gustave Roussy, **Paris Sud University, France** Topics: Imaging and therapy of Thyroid Tumors, Prostate Cancer, Neuroendocrine Tumors

2014-2016:

Master Program, Paris Sud University.

Topics: Thyroid tumors, Imaging of Head and neck Cancer

2014-2016:



UNIVERSITÀ DEGLI STUDI DI TORINO

School of Radiology Technicians, IFMEM. Paris Sud University

Topics: Sentinel Lymphnode, Bone scintigraphy, PET imaging

Thyroid Cancer Imaging and Therapy

PUBLICATIONS

Authors of more than 80 scientific contributions, published in peer-reviewed international journals.

For a detailed list of the publication: <https://www.mendeley.com/authors/23970206000/>

Scientific metrics as reported in SCOPUS (01.04.2020):

H INDEX: 29

N Documents: 95

N citations: 2906

Selection of the best 20 publications (2010-2021):

1. **Désirée Deandreis**, Aline Maillard, Slimane Zerdoud, Claire Bournaud, Lavinia Vija, Christophe Sajous, Marie Terroir, Laurence Leenhardt, Martin Schlumberger, Isabelle Borget³, Sophie Leboulleux. RADTHYR: an open-label, single-arm, prospective multicenter phase II trial of Radium-223 for the treatment of bone metastases from radioactive iodine refractory differentiated thyroid cancer **Eur J Nucl Med Mol Imaging**. **2021** Feb 23 doi: 10.1007/s00259-021-05229-y. Online ahead of print.

2. Monica Finessi, Alessandro Bisceglia, Roberto Passera, Ruth Rossetto Giaccherino, Loredana Pagano, Giancarlo Castellano, Ezio Ghigo, Gianni Bisi, **Désirée Deandreis**. Predictive factors of a worse response to radioactive Iodine-131 treatment in hyperthyroidism: outcome analysis in 424 patients. A single centre experience. **Endocrine** **2021** Jan 5. doi: 10.1007/s12020-020-02573-1.

3. Virginia Liberini, Bruno De Santi, Osvaldo Rampado, Elena Gallio, Beatrice Dionisi, Francesco Ceci, Giulia Polverari, Philippe Thuillier, Filippo Molinari, **Désirée Deandreis**. Impact of segmentation and discretization on radiomic features in ⁶⁸Ga-DOTA-TOC PET/CT images of neuroendocrine tumor **EJNMMI Phys** **2021** Feb 27;8(1):21. doi: 10.1186/s40658-021-00367-6.

4. Virginia Liberini, Osvaldo Rampado, Elena Gallio, Bruno De Santi, Francesco Ceci, Beatrice Dionisi, Philippe Thuillier, Libero Ciuffreda, Alessandro Piovesan, Federica Fioroni, Annibale Versari, Filippo Molinari, **Désirée Deandreis**. ⁶⁸Ga-DOTATOC PET/CT-Based Radiomic Analysis and PRRT Outcome: A Preliminary Evaluation Based on an Exploratory Radiomic Analysis on Two Patients **Front Med (Lausanne)** **2021** Jan 26;7:601853 doi:10.3389/fmed.2020.601853.

5. Virginia Liberini, Martin W Huellner, Serena Grimaldi, Monica Finessi, Philippe Thuillier, Alfredo Muni, Riccardo E Pellerito, Mauro G Papotti, Alessandro Piovesan, Emanuela Arvat, **Désirée Deandreis**. The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future. **Diagnostics (Basel)**. **2020** Dec 12;10(12):1083. doi: 10.3390/diagnostics10121083.



6. Polverari G, Ceci F, Bertaglia V, Reale ML, Rampado O, Gallio E, Passera R, Liberini V, Scapoli P, Arena V, Racca M, Veltri A, Novello S, **Deandrei D**. ¹⁸F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nscl Treated with Immunotherapy as Predictors of Therapy Response and Survival. **Cancers (Basel)**. 2020 May 5;12(5):1163. doi: 10.3390/cancers12051163.
7. **Deandrei D**, Guarneri A, Ceci F, Lillaz B, Bartoncini S, Oderda M, Nicolotti DG, Pilati E, Passera R, Zitella A, Bellò M, Parise R, Carlevato R, Ricardi U, Gontero P. ⁶⁸Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC): a prospective single-centre study in patients eligible for salvage therapy. **Eur J Nucl Med Mol Imaging**. 2020 Apr 20. doi: 10.1007/s00259-020-04809-8.
8. Salaün PY, Abgral R, Malard O, Querellou-Lefranc S, Quere G, Wartski M, Coriat R, Hindie E, Taieb D, Tabarin A, Girard A, Grellier JF, Brenot-Rossi I, Groheux D, Rousseau C, **Deandrei D**, et al. Good clinical practice recommendations for the use of PET/CT in oncology. **Eur J Nucl Med Mol Imaging**. 2020 Jan;47(1):28-50. Doi: 10.1007/s00259-019-04553-8.
9. Morris MJ, Loriot Y, Sweeney CJ, Fizazi K, Ryan CJ, Shevrin DH, Antonarakis ES, Pandit-Taskar N, **Deandrei D**, et al. Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. **Eur J Cancer**. 2019 Jun;114:107-116. Doi: 10.1016/j.ejca.2019.04.007.
10. Schlumberger M, Leboulleux S, Catargi B, **Deandrei D**, et al. Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial. **Lancet Diabetes Endocrinol**. 2018 Aug;6(8):618-626. doi: 10.1016/S2213-8587(18)30113-X.
11. Grimaldi S, Young J, Kamenicky P, Hartl D, Terroir M, Leboulleux S, Berdelou A, Hadoux J, Hescot S, Remy H, Baudin E, Schlumberger M, **Deandrei D**. Challenging pre-surgical localization of hyperfunctioning parathyroid glands in primary hyperparathyroidism: the added value of ¹⁸F-Fluorocholine PET/CT. **Eur J Nucl Med Mol Imaging**. 2018 Sep;45(10):1772-1780. doi:10.1007/s00259-018-4018-z.
12. **Deandrei D**, Rubino C, Tala H, Leboulleux S, Terroir M, Baudin E, Larson S, Fagin JA, Schlumberger M, Tuttle RM. Comparison of Empiric Versus Whole- Body/-Blood Clearance Dosimetry-Based Approach to Radioactive Iodine Treatment in Patients with Metastases from Differentiated Thyroid Cancer. **J Nucl Med**. 2017 May;58(5):717-722. doi: 10.2967/jnumed.116.179606.
13. Borget I, Bonastre J, Catargi B, **Déandréis D**, Zerdoud S, Rusu D, Bardet S, Leenhardt L, Bastie D, Schvartz C, Vera P, Morel O, Benisvy D, Bournaud C, Bonichon F, Kelly A, Toubert ME, Leboulleux S, Journeau F, Benhamou E, Schlumberger M. Quality of Life and Cost-Effectiveness Assessment of Radioiodine Ablation Strategies in Patients With Thyroid Cancer: Results From the Randomized Phase III ESTIMABL Trial. **J Clin Oncol**. 2015 Sep 10;33(26):2885-92. doi:10.1200/JCO.2015.61.6722.



14. Gouy S, Morice P, Narducci F, Uzan C, Martinez A, Rey A, Bentivegna E, Pautier P, **Deandreis D**, Querleu D, Haie-Meder C, Leblanc E. Prospective multicenter study evaluating the survival of patients with locally advanced cervical cancer undergoing laparoscopic para-aortic lymphadenectomy before chemoradiotherapy in the era of positron emission tomography imaging. **J Clin Oncol.** **2013** Aug 20;31(24):3026-33. doi: 10.1200/JCO.2012.47.3520.
15. Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, **Deandreis D**, Pentlow KS, Zanzonico PB, Haque S, Gavane S, Ghossein RA, Ricarte-Filho JC, Domínguez JM, Shen R, Tuttle RM, Larson SM, Fagin JA. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. **N Engl J Med.** **2013** Feb 14;368(7):623-32. doi:10.1056/NEJMoa1209288.
16. Schlumberger M, Catargi B, Borget I, **Deandreis D**, et al. Tumeurs de la Thyroïde Refractaires Network for the Essai Stimulation Ablation Equivalence Trial. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. **N Engl J Med.** **2012** May 3;366(18):1663-73. doi: 10.1056/NEJMoa1108586.
17. **Deandreis D**, Al Ghuzlan A, Auperin A, Vielh P, Caillou B, Chami L, Lumbroso J, Travagli JP, Hartl D, Baudin E, Schlumberger M, Leboulleux S. Is (18)F-fluorodeoxyglucose-PET/CT useful for the presurgical characterization of thyroid nodules with indeterminate fine needle aspiration cytology? **Thyroid.** **2012** Feb;22(2):165-72. doi: 10.1089/thy.2011.0255.
18. **Deandreis D**, Al Ghuzlan A, Leboulleux S, Lacroix L, Garsi JP, Talbot M, Lumbroso J, Baudin E, Caillou B, Bidart JM, Schlumberger M.
Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?
Endocr Relat Cancer. **2011** Jan 13;18(1):159-69. doi: 10.1677/ERC-10-0233.
19. **Deandreis D**, Leboulleux S, Dromain C, Auperin A, Coulot J, Lumbroso J, Deschamps F, Rao P, Schlumberger M, de Baère T. Role of FDG PET/CT and chest CT in the follow-up of lung lesions treated with radiofrequency ablation. **Radiology.** **2011** Jan;258(1):270-6. doi: 10.1148/radiol.10092440.
20. Poisson T, **Deandreis D**, Leboulleux S, Bidault F, Bonniaud G, Baillet S, Aupérin A, Al Ghuzlan A, Travagli JP, Lumbroso J, Baudin E, Schlumberger M.
18F-fluorodeoxyglucose positron emission tomography and computed tomography in anaplastic thyroid cancer.
Eur J Nucl Med Mol Imaging. **2010** Dec;37(12):2277-85. doi: 10.1007/s00259-010-1570-6.

CONTRIBUTION in NATIONAL/ INTERNATIONAL MEETING

I attended and submitted abstracts to the main congresses in Nuclear Medicine (EANM, SNMMI, AIMN), Endocrinology and Oncology since 2003 to present.

Selection of the best presented abstract in the last five years (2015-2020):



-Predictive value of volumetric parameters of pretherapeutic 18 F-FDG-PET/CT for response to Lenvatinib in patients treated for iodine-refractory differentiated thyroid cancer.

Elena Califaretti, Philippe Thuillier, Virginia Liberini, Alberto Ragni, Alice Nervo, Marco Gallo, Alessandro Piovesan, Manuela Arvat, Serena Grimaldi, Desiree Deandreis.

TOP RATED ABSTRACT ORAL PRESENTATION Annual Meeting of European Association of Nuclear Medicine (EANM), October 22nd-28th 2020 (webconference).

-68Ga-PSMA-11 PET/CT in hormone-naïve recurrent prostate cancer: a prospective, single-center study in patients eligible for salvage therapy". F. Ceci, D. G. Nicolotti, E. Pilati, A. Guarneri, B. Lillaz, R. Passera, V. Liberini, M. Finessi, M. Bellò, P. Gontero, U. Ricardi, D. Deandreis.

ORAL PRESENTATION European Association of Nuclear Medicine Annual Meeting (EANM), Barcelona, October 12-16th 2019.

-Impact of late pelvic acquisition on 68Ga-PSMA-11 PET/CT positivity rate and inter-rater reliability analysis. F. Ceci, D. G. Nicolotti, E. Pilati, B. Dionisi, M. Bellò, D. Deandreis.

ORAL PRESENTATION European Association of Nuclear Medicine Annual Meeting (EANM), Barcelona, October 12-16th 2019.

-A Study of Radiomic Features Robustness for 68Ga-DOTATOC PET/CT in Neuroendocrine Tumors.

Liberini V, De Santi B, Gallio E, Pilati E, Finessi M, Bellò M, Papotti MG, Maletta F, Volante M, Bisi G, Molinari F, Deandreis D.

ORAL PRESENTATION European Association of Nuclear Medicine Annual Meeting (EANM), Barcelona, October 12-16th 2019.

-Outcome analysis after Radioactive Iodine-I131 Treatment in 424 patients with hyperthyroidism.

M Finessi, A Di Bisceglie, R Passera, R Rossetto Giaccherino, G Castellano, G Bisi, D Deandreis.

e- POSTER European Association of Nuclear Medicine Annual Meeting (EANM), Barcelona, October 12-16th 2019; ORAL PRESENTATION at Italian Association of Nuclear Medicine (AIMN), Rimini April 11-14th 2019.

-Efficacy of radium 223 in radioactive iodine refractory bone metastases from thyroid cancer: Preliminary results of a single arm Phase II trial.

Désirée Deandreis, Aline Maillard, Isabelle Borget, Slimane Zerdoud, Claire Bournaud, Laurence Leenhardt, Marie Terroir, Abir Al Ghuzlan, Martin Schlumberger, Sophie Leboulleux.

ORAL PRESENTATION World congress on thyroid cancer 3.5 (WTCT). Rome June 20th-22nd 2019.

- Efficacy of radium 223 in radioactive iodine refractory bone metastases from thyroid cancer: Preliminary results of a single arm Phase II trial.

Désirée Deandreis, Aline Maillard, Isabelle Borget, Slimane Zerdoud, Claire Bournaud, Laurence Leenhardt, Marie Terroir, Abir Al Ghuzlan, Martin Schlumberger, Sophie Leboulleux.

TOP RATED ABSTRACT, ORAL PRESENTATION

Annual Meeting of American Society of Nuclear Medicine (SMMMI). Anaheim California. 21-25th June 2019.

- Impact of F18-Fluorocholine PET/CT in the pre-surgical work up of primary hyperparathyroidism



UNIVERSITÀ DEGLI STUDI DI TORINO

S. Grimaldi, J. Young, P. Kamenicky, D. Hartl, M. Terroir, S. Leboulleux, E. Baudin, M. Schlumberger, D. Deandreis.

ORAL PRESENTATION European Association of Nuclear Medicine (EANM) Annual Meeting, Vienna, October 21-25, 2017.

- Impact sur la survie d'une approche empirique ou dosimétrique du traitement par iode radioactive des métastases à distance du cancer de la thyroïde différencié.

Deandreis D, Rubino C, Tala H, Leboulleux S, Terroir M, Baudin E, Larson S, Fagin J, Schlumberger M, Tuttle RM.

ORAL PRESENTATION. Société Française de Médecine Nucléaire. 2eme Journées Francophones de Médecine Nucléaire. Grenoble, May 19th-22th 2016.

- Comparison of empiric fixed dosing with a whole body/blood clearance dosimetry based management approach to radioactive iodine treatment in patients with RAI avid distant metastases from differentiated thyroid cancer.

Deandreis D, Tala H, Rubino C, Leboulleux S, Baudin E, Larson S, Schlumberger M, Tuttle R. M.

ORAL PRESENTATION International Thyroid Cancer (ITC) Orlando Florida USA, October 18-23. 2015.

INVITED SPEAKERS TO NATIONAL AND INTERNATIONAL CONFERENCES

Selection of main invited lectures

1. Contribute of RLT with Lutathera with NET patient management. **5th EUS ERCP CONNECTION** 17-18 December 20, 2020.
2. Update of Radioactive treatment in hyperthyroidism. Joint Symposium EANM/ETA/ESES. **European Association of Nuclear Medicine (EANM) Annual Meeting**, October 22nd-28th 2020 (webconference).
3. Consensus Italiana di Medicina Nucleare sulla gestione del Carcinoma Differenziato della Tiroide. **Associazione Italiana di Medicina Nucleare (AIMN)**. Chairman and speaker Rome January 24th 2020.
4. FDG PET in Melanoma. **Journées des Médecine Nucléaire de la Société Française de Médecine Nucléaire**. Serre Chevalier, January 20th-24th 2020
5. False positive results of 68 Ga PSMA PET. **11th European Multidisciplinary Meeting on Urological Cancers (EMUC)**. November 14th-17th 2019.
6. Definition of refractory Thyroid Cancer. RAI treatment: Dosimetry or not. **World congress on thyroid cancer 3.5 (WTCT). Plenary Session**. June 20th-22nd Rome 2019.



7. Thyroid cancer and recent guidelines recommendations. **Annual Meeting of Associazione Italiana Medicina Nucleare (AIMN)**. Rimini, April 11-14th 2019.
8. Clinical trial RAD THYR. National Meeting of Tuthyref (**French National network of Refractory Thyroid cancer**) Strasburg, France. January 18th 2019.
9. Defining Non-Radioiodine-Avid Thyroid Cancer. Session Molecular Mechanism of Iodine Resistance and Their Clinical Implications. **Joint Symposium (Thyroid / ETA-CRN). Annual Meeting of European Association of Nuclear Medicine, (EANM)**. Dusseldorf. October 13-17 **2018**.
10. Pro and Con Discussion. Dosimetrically Determined Activities in Advanced DTC. **Pre-Congress Symposium (Thyroid/Dosimetry). Annual Meeting of European Association of Nuclear Medicine, (EANM)**. Dusseldorf. 2018 October 13th-17 th **2018**.
11. Immuno-PET. Immunotherapy course in Oncology. **Associazione Italiana di Oncologia Medica (AIOM)/ Italian Association of Medical Oncology**. Turin, September 5th-6th **2018**.
12. Theranostic and Radioactive iodine. XXVI Corso di aggiornamento in Medicina Nucleare ed Imaging Molecolare. (National course in Nuclear Medicine and Molecular Imaging) **Associazione Italiana Medicina Nucleare (AIMN)**. Bergamo (Italy) May 24th-26th **2018**.
13. Radium 223:3 years of experience in Italy. XXVI Corso di aggiornamento in Medicina Nucleare e Imaging Molecolare. (National course in Nuclear Medicine and Molecular Imaging) **Associazione Italiana Medicina Nucleare (AIMN)**. Bergamo (Italy) May 24th-26th **2018**.
14. Expert meeting on RAI refractory Differentiated Thyroid Cancer. **Italian Thyroid Cancer Observatory Foundation (ITCO)**. Rome April 12th **2018**.
15. Radium 223 in DTC patients with bone metastases. **ITOG/EORTC** (International thyroid Oncology Group/ European Organization for Research and Treatment of cancer). Rome May 7th-8th **2015**.
16. Trattamento con il Radio 223 del tumore della tiroide metastatico/Treatment with radium223 of metastatic thyroid cancer. **5th Rome Thyroid Cancer Forum**. Rome, May 8th-9th **2015**.
17. FDG PET/CT in the response assessment to ablative therapy. **European Congress of Radiology (ECR)**. Vienna, March 6-10 **2014**.
18. Radiometabolic treatment : ALPHA EMITTERS. **XXIIemes Journées de Médecine Nucléaire et Cancérologie Endocrinienne**. Gustave Roussy, Villejuif March 21 **2014**.
19. Radiothérapie Métaboliques : Nouvelles cibles. **Journée de Recherche du Gustave Roussy**.Tours (France), March 13-14 **2014**.



20. Intérêt de la dosimétrie pour la prédiction de la réponse tumorale à l'Iode 131. **XXIemes Journées de Médecine Nucléaire et Cancérologie Endocrinienne**. Gustave Roussy, Villejuif March 15 **2013**.
21. FDG PET/CT in the response assessment to ablative therapy. **European Congress of Radiology (ECR)**. Vienna March 7th-11th **2013**
22. State-of-the-art of imaging in response assessment: PET/CT. **3rd European Conference on Interventional Radiology (ECIO)**. Florence, April 25th-28th **2012**.
23. Evaluation de réponse au traitement local des métastases osseuse. **XXemes Journées de Médecine Nucléaire et Cancérologie Endocrinienne**. Gustave Roussy, Villejuif March 16th **2012**.
24. Médecine Nucléaire : évaluation de la réponse métabolique au traitement systémique et local par TEP au FDG. **Journée de Recherche du Gustave Roussy**. Tours, March 8-9 **2012**.
25. Update in Radioiodine Therapy with Recombinant Human TSH. **XXII Congress of South American Nuclear Medicine Society ALABISMN**. Porto de Galinhas, Brasil, September 28th –October 1st **2011**.
26. Treatment of low risk thyroid cancer patients with 30 mCi. **XXII Congress of South American Nuclear Medicine Society ALABISMN**. Porto de Galinhas, Brasil, September 28–October 1 **2011**.
27. FDG PET in thyroid cancer. Thyroid Conference. **Memorial Sloan-Kettering Cancer Center**, January 7th **2011**.
28. TEP au FDG et évaluation de la réponse au traitement. **18emes Journées de Médecine Nucléaire et Cancérologie Endocrinienne**. Gustave Roussy, Villejuif March 16 **2010**.
29. Recommandations de l'utilisation de la TEP-FDG (fluorodeoxyglucose) dans la caractérisation des nodules thyroïdiens. Proposition de Consensus. **26eme Congrès de la Société Française d'Endocrinologie (SFE)**. Nice October 7-10 **2009**.
30. Histologie, mitoses, nécroses, TEP au FDG. Quels facteurs pronostiques pour les cancers thyroïdiens métastatiques ? **Réunion Groupe de travail en pathologie thyroïdienne**. Dijon, June 2009.
31. Rôle de la TEP au fluorodesoxyglucose (TEP-FDG) dans la caractérisation des nodules de la thyroïde à cytologie folliculaire indéterminée : résultats préliminaires. **Réunion du Groupe de Recherche sur la Thyroïde (GTE)**, Paris, March 15th **2009**.
32. Médecine Nucléaire. Cas Cliniques. **17emes Journées de Médecine Nucléaire et Cancérologie Endocrinienne**. Gustave Roussy, Villejuif. March 20th **2009**.



- 33. Tomographie à émission des positions. Cas Cliniques. 16eme Journée de Médecine Nucléaire et Cancérologie Endocrinienne. Gustave Roussy, Villejuif March 21st 2008.**

SCIENTIFIC MEETING FACULTY/CHAIRMAN/MODERATOR

1. Consensus Italiana di Medicina Nucleare sulla gestione del Carcinoma Differenziato della Tiroide. Chairman. Rome January 24th 2020
2. Journées des Médecine Nucléaire de la Société Française de Médecine Nucléaire. Chairman. Serre Chevalier, January 20th-24th 2020.
3. 11th European Multidisciplinary Meeting on Urological Cancers (EMUC). 2019
4. Home of Therapies. Moderator Plenary Session: Follow up of Thyroid cancer. Riccione (Italy). April 6th-7th 2018.
5. 11mo Congresso Associazione italiana della tiroide (AIT). AIT Annual Meeting. XXXV Giornate della Tiroide. Torino. November 30- December 2 2017
6. CA.P DAYS. Incontri di aggiornamento sul carcinoma prostatico. A.O.U Città della Salute e della Scienza, November 27 Turin 2017.
7. Regional Training course of Città della Salute e della Scienza hospital on SPECT/CT. Turin, Istituto Rosmini, October 7 2017.
8. Regional Training course of Città della Salute e della Scienza hospital on Functional Imaging in Neurology. Turin, Istituto Rosmini, April 1 2017.
9. NORTH WEST Macroregional Training Meeting (SIE/AIOM): Treatment of Refractory thyroid Cancer, Città della Salute e della Scienza (Special guests: Prof. M. Schlumberger Gustave Roussy, Dr MR Tuttle MSKCC). Turin, March 15 2017.

CONTRIBUTION in MONOGRAPHS and BOOKS

1. Chapter: Colorectal Cancer.
Polverari G, Penna D, Deandreis D, Pelosi E.
In: Strauss HW, Mariani G, Volterrani D, Larson SM. Nuclear Oncology: Pathophysiology and Clinical Applications. Ed. Springer (**2021**).
2. **Editorial Board: European Nuclear Medicine Guide.** A joint publication of EANM and UEMS/EBNM (European Association of Nuclear Medicine, European Union of Medical Specialists/ European Board of Nuclear Medicine). **Version 2020.**
3. Chapter 47: Cancer staging with 18F -FDG PET in hyperglycemic patients.
Finessi M, Liberini V, Deandreis D.



UNIVERSITÀ DEGLI STUDI DI TORINO

In: Joel Faintuch, Salomao Faintuch. Obesity and Diabetes. Ed Springer **2020**

4. Chapter: Radioactive iodine in hyperthyroidism: side effects.
Campenni A, Deandreis D, Finessi M, RM Ruggeri, Baldari S.
In : Giovanella Luca. Nuclear Medicine Therapy. Pag 11-13. Ed Springer. **2019**
5. Chapter Diagnostic Applications of Nuclear Medicine: Colorectal Cancer.
Ettore Pelosi, Désirée Deandreis, Laura Cassalia, Daniele Penna (**2017**).
Nuclear Oncology. In: Strauss H. William, Nuclear Oncology. p. 777-797, Ed Springer.
6. Chapter: A patient with follicular thyroid cancer and a painful bone metastasis at risk for pathological fracture. Deandreis D.
In: D.S. Cooper, C Durante. Thyroid Cancer: A Case-Based Approach. Pag: 293-305. Ed. Springer (**2016**). **Updated version 2020 in print.**

EDITORIAL BOARD/REVIEWER

British Medical Journal of Cancer (Associate Editor); Springer Nature, ISSN: 1471-2407, IF:3.645

Quarterly Journal of Nuclear Medicine and Molecular Imaging (Editorial Board, Guest Editor); Ed. Minerva Medica; ISSN: 1824-4785; IF: 2.481

Cancers; Editorial Board for Nuclear Medicine Section (ISSN 2072-6694; IF 6.1)

Clinical and Translational Imaging; Editorial Board; Ed. Springer Nature (IF 2.5).

Frontiers in Medicine ; Editorial Board Ed Springer (IF 3.7)

European Journal of Nuclear Medicine and Molecular Imaging, Springer, ISSN: 1619-7070 (print version), IF: 7.277. Reviewer

Journal of Nuclear Medicine, Publisher: Society of Nuclear Medicine and Molecular Imaging, ISSN: 0161-5505 (print), IF: 7.88. Reviewer

Thyroid, Official Journals of the American Thyroid Association, Mary Ann Liebert Inc. Publishers, (ISSN: 1050-7256 IF:5.515.) Reviewer

Radiotherapy and Oncology, Journal of the European Society for Radiotherapy and Oncology and affiliated to the Canadian Association of Radiation Oncology, Elsevier, ISSN: 0167-8140, IF: 4.328. Reviewer

Journal of Endocrinological Investigation, Official Journal of Italian Society of Endocrinology (SIE), Springer, ISSN: 1720-8386, IF:2.633. Reviewer



UNIVERSITÀ DEGLI STUDI DI TORINO

Endocrine, International Journal of Basic and Clinical Endocrinology, Springer, (ISSN: 1355-008X, IF: 3.131) Reviewer

European Journal of Radiology; Elsevier, ISSN: 0720-048X, IF: 2.462. Reviewer 21 The Journal of Nuclear Medicine, Publisher: Society of Nuclear Medicine and Molecular Imaging (ISSN: 0161-5505 IF :6.646). Reviewer

CONTRIBUTION in GUIDELINES

Editorial Board SOR (Standards, Options and Recommendations) du bon usage de la TEP en Oncologie” and Author of Chapter: PET and Melanoma

SFMN, Société Française de Médecine Nucléaire. INCA, Institut National du cancer Published in Bull Cancer. 2019 Jan 22. pii: S0007-4551(19)30018-9. doi: 10.1016/j.bulcan.2019.01.002 and in **European Journal of Nuclear Medicine 2020 Doi: 10.1007/s00259-019-04553-8.**

Editorial Board for Italian Association of Medical Oncology (AIOM): Guidelines for Thyroid Cancer. Version 2020.

EXPERT OPINION

2018-to present: Expert for Délégation à la Recherche Clinique et à l'Innovation (DRCI), Assistance Publique – Hôpitaux de Paris. France

2017-2018: Editorial Project sponsored by Novartis

NEXT: Multidisciplinary approach of patients with neuroendocrine tumors.

2013-to present:

-Canceropole Grand Sud Ouest/ GIRCI SOOM (Groupement Interrégional de Recherche Clinique et d'Innovation)

-Dutch Cancer Society

-INCA, Institut National du cancer

CLINICAL TRIALS/ FUNDING (GCP certification 04/06/2020);

PRINCIPAL INVESTIGATOR

1. **PSMA_CMT_2021 (NP 602/2020)** Preliminary evaluation with ⁶⁸Ga PSMA PET/CT in patients with metastatic medullary thyroid carcinoma. AOU Città della Salute e della Scienza, Turin.
2. **PET Thyroid TKI (NP 528/2020):** Predictive value of volumetric parameters at baseline ¹⁸F-FDG-PET/CT of response to Lanvatinib in patient with radioactive iodine refractory thyroid tumors. Multicentric, Italy.
3. **NET PET tumor burden study (NP 536/2020):** Prognostic value of tumor burden on ⁶⁸Ga-DOTATOC and ¹⁸F-FDG PET/CT in patients with neuroendocrine tumors. AOU Città della Salute e della Scienza, Turin.



UNIVERSITÀ DEGLI STUDI DI TORINO

4. **Lung-NET Radiomics_2020 (NP 459/2020):** Lung carcinoid characterization by histopathology and radiomic analysis on ^{18}F -FDG PET/TC. AOU Città della Salute e della Scienza, Turin.
5. **PSMA-Staging_2020 (NP 426/2020):** Multimodal approach with ^{68}Ga -PSMA-11 PET/TC in patients with high-risk prostate cancer candidate to radical prostatectomy. AOU Città della Salute e della Scienza, Turin.
6. **Grant by CRT (Cassa di Riparmio di Torino) Foundation (2019):** Project Title: "Radiomic in Neuroendocrine Tumors: a method to evaluate tumoral heterogeneity".
7. **Research Grant by Department of Medical Sciences, University of Turin (RILO 2017-2019)**
Project: "Ga68 DOTATOC PET/CT as a new prognostic tool and predictive value of response to treatment in metastatic Neuroendocrine Tumor"
Monocentric Study AOU Città della Salute e della Scienza hospital, Turin.
8. **NCT02390934 (2015-2016)**
RESEARCH GRANT: Bayer Healthcare
Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer (RAD-THYR)
Monocentric study/ Gustave Roussy
9. **NCT 0203697 (BAYER 16507) (2015-2016)**
Sponsor: Bayer Healthcare Standard Dose versus high Dose and Versus Extended Standard Dose Radium223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the bone.
Multicenter Europe/USA/ASIA
Principal Investigator for Gustave Roussy.
10. **2010: Research Grant by Fondation de France** (www.fdf.org n° 2010-12521):
Project: "Prediction of response to radioactive iodine by ^{124}I PET/CT in metastatic thyroid cancer"

CO-INVESTIGATOR/CO-PARTICIPANT

1. **2018-2019: Rete Oncologica Piemonte e Valle d'Aosta. THERA_DOSE. Dosimetry in thyroid cancer.**
2. **2017-present: Co-participant in TESEO project (Traguardi di eccellenza nelle Scienze mediche esplorando le omiche) Excellence project funded by the Italian Minister of University and Research.** Department of Medical Sciences, University of Turin.
3. **2017: Funding for EuBI-NodoIM-TO project (Italian Euro-BioImaging Network in Molecular Imaging)**
Reference: Prof Silvio Aime, Department of Molecular Biotechnology and Health Sciences, University of Turin
4. **2017: Treatment of Metastatic prostate cancer castration resistant (mCRPC) with $^{223}\text{RaCl}_2$: response evaluation with a novel tracer ^{68}Ga -PSMA PET molecular imaging (CALIPSO). Clinical Phase II trial .**
Multicentric Study (PI: Dr Carlo Poti). EudraCT 2017-001395-38.
Principal Investigator for Città della Salute e della Scienza Hospital of Turin
5. **2016:P-5315**
Grant: AOU Città della Salute e della Scienza, Turin.
PSMA PET /CT in the evaluation of prostate cancer recurrence (P.I. Prof P. Gontero).
Monocenter prospective study, Città della Salute e della Scienza Hospital of Turin



6. **NCT01403324**

Grant: Gustave Roussy

Comparison of Dosimetry After rhTSH or Withdrawal of Thyroid Hormone in Metastatic or Locally Advanced Thyroid Cancer

Monocenter Study, Gustave Roussy (PI Dr Sophie Leboulleux)

7. **NCT01837745**

Grant: INCA Institut National du cancer

Differentiated Thyroid Cancer: Is there a need for Radioiodine Ablation in Low risk patients?

Multicenter Study, Europe (PI Dr Sophie Leboulleux)

8. **NCT02230176**

Grant: National Cancer Institute, France, Advanced Accelerator Applications

Antitumor Efficacy of Peptide Receptor Radionuclide Therapy with Lutetium-Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-Differentiated Neuroendocrine Pancreatic Carcinoma: First Randomized Phase II (OCCLURANDOM). (PI Dr Eric Baudin)

Multicenter Study/Europe

9. **NCT01106352**

Sponsor: Bayer Healthcare

Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)

Multicenter study Europe/USA

Turin, April 20th 2021

Prof. Désirée Deandreis

Director - Nuclear Medicine Division
AOU Città della Salute e della Scienza di Torino
Associate Professor in Nuclear Medicine
Director – Nuclear Medicine Residency Program
Department of Medical Sciences
University of Turin



List of publications_ **DESIREE DEANDREIS**

1: Liberini V, Laudicella R, Capozza M, Huellner MW, Burger IA, Baldari S, Terreno E, Deandreis D.

The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers.

Molecules. 2021 Apr 11;26(8):2201. doi: 10.3390/molecules26082201.

PMID: 33920423; PMCID: PMC8069316.

2: Bioletto F, Barale M, Parasiliti-Caprino M, Prencipe N, Berton AM, Procopio M, Deandreis D, Ghigo E.

Comparison of the diagnostic accuracy of ¹⁸F-Fluorocholine PET and ¹¹C-Methionine PET for parathyroid localization in primary hyperparathyroidism: a systematic review and meta-analysis.

Eur J Endocrinol. 2021 Apr 1:EJE-21-0038.R1. doi: 10.1530/EJE-21-0038. Epub ahead of print. PMID: 33886494.

3: Liberini V, Messerli M, Husmann L, Kudura K, Grünig H, Maurer A, Skawran S, Orita E, Pizzuto DA, Deandreis D, Dummer R, Mangana J, Mihic-Probst D, Rupp N, Huellner MW. Improved detection of in-transit metastases of malignant melanoma with BSREM reconstruction in digital [¹⁸F]FDG PET/CT.

Eur Radiol. 2021 Mar 25. doi: 10.1007/s00330-021-07852-7. Epub ahead of print. PMID: 33768288.

4: Giovanella L, Ruggeri RM, Petranović Ovčariček P, Campenni A, Treglia G, Deandreis D. SARS-CoV-2-related thyroid disorders: a synopsis for nuclear medicine thyroidologists.

Eur J Nucl Med Mol Imaging. 2021 Mar 25. doi: 10.1007/s00259-021-05316-0. Epub ahead of print. PMID: 33765218.

5: Giovanella L, Ruggeri RM, Ovčariček PP, Campenni A, Treglia G, Deandreis D.

Prevalence of thyroid dysfunction in patients with COVID-19: a systematic review.

Clin Transl Imaging. 2021 Mar 11:1-8. doi: 10.1007/s40336-021-00419-y.

Epub ahead of print. PMID: 33728279; PMCID: PMC7950424.

6: Thuillier P, Liberini V, Rampado O, Gallio E, De Santi B, Ceci F, Metovic J, Papotti M, Volante M, Molinari F, Deandreis D.

Diagnostic Value of Conventional PET Parameters and Radiomic Features Extracted from ¹⁸F-FDG-PET/CT for Histologic Subtype Classification and Characterization of Lung Neuroendocrine Neoplasms.

Biomedicines. 2021 Mar 10;9(3):281. doi: 10.3390/biomedicines9030281. PMID: 33801987; PMCID: PMC8001140.

7: Liberini V, De Santi B, Rampado O, Gallio E, Dionisi B, Ceci F, Polverari G, Thuillier P, Molinari F, Deandreis D.

Impact of segmentation and discretization on radiomic features in ⁶⁸Ga-DOTA-TOC PET/CT images of neuroendocrine tumor.



EJNMMI Phys. 2021 Feb 27;8(1):21. doi: 10.1186/s40658-021-00367-6. PMID: 33638729; PMCID: PMC7914329.

8: Deandreis D, Maillard A, Zerdoud S, Bournaud C, Vija L, Sajous C, Terroir M, Leenhardt L, Schlumberger M, Borget I, Lebouilleux S.

RADTHYR: an open-label, single-arm, prospective multicenter phase II trial of Radium-223 for the treatment of bone metastases from radioactive iodine refractory differentiated thyroid cancer.

Eur J Nucl Med Mol Imaging. 2021 Feb 23. doi:

10.1007/s00259-021-05229-y. Epub ahead of print. PMID: 33619600.

9: Albano D, Bertagna F, Alongi P, Baldari S, Baldoncini A, Bartolomei M, Boccaletto F, Boero M, Borsatti E, Bruno A, Burrioni L, Capocchetti F, Castellani M, Cervino AR, Chierichetti F, Ciarmiello A, Corso A, Cuocolo A, De Rimini ML, Deandreis D, Dottorini ME, Esposito F, Farsad M, Gasparini M, Grana CM, Gregianin M, Guerra L, Loreti F, Lupi A, Martino G, Milan E, Modoni S, Morbelli S, Muni A, Nicolai E, Palumbo B, Papa S, Papaleo A, Pellerito R, Poti C, Romano P, Rossetti C, Rossini P, Rubini G, Ruffini L, Sacchetti G, Savelli G, Schiavariello S, Sciagrà R, Sciuto R, Seregini E, Sestini S, Sicolo M, Spanu A, Storto G, Balducci MT, Trifirò G, Versari A, Vignati A, Volterrani D, Calcagni ML, Marzola MC, Garufo A, Evangelista L, Maroldi R, Schillaci O, Giubbini R; On the behalf of Italian Association of Nuclear Medicine (AIMN).

Prevalence of interstitial pneumonia suggestive of COVID-19 at ¹⁸F-FDG PET/CT in oncological asymptomatic patients in a high prevalence country during pandemic period: a national multi-centric retrospective study.

Eur J Nucl Med Mol Imaging. 2021 Feb 9:1–12. doi: 10.1007/s00259-021-05219-0. Epub ahead of print. PMID: 33560453; PMCID: PMC7871520.

10: Gouy S, Seebacher V, Chargari C, Terroir M, Grimaldi S, Ilenko A, Maulard A, Genestie C, Leary A, Pautier P, Morice P, Deandreis D.

False negative rate at ¹⁸F-FDG PET/CT in para-aortic lymphnode involvement in patients with locally advanced cervical cancer: impact of PET technology.

BMC Cancer. 2021 Feb 6;21(1):135. doi: 10.1186/s12885-021-07821-9. PMID: 33549033; PMCID: PMC7866875.

11: Liberini V, Rampado O, Gallio E, De Santi B, Ceci F, Dionisi B, Thuillier P, Ciuffreda L, Piovesan A, Fioroni F, Versari A, Molinari F, Deandreis D.

⁶⁸Ga-DOTATOC PET/CT-Based Radiomic Analysis and PRRT Outcome: A Preliminary Evaluation Based on an Exploratory Radiomic Analysis on Two Patients.

Front Med (Lausanne). 2021 Jan 26;7:601853. doi: 10.3389/fmed.2020.601853. PMID: 33575262; PMCID: PMC7870479.

12: Finessi M, Bisceglia A, Passera R, Rossetto Giaccherino R, Pagano L, Castellano G, Ghigo E, Bisi G, Deandreis D.

Predictive factors of a worse response to radioactive Iodine-I131 treatment in hyperthyroidism: outcome analysis in 424 patients. A single centre experience.

Endocrine. 2021 Jan 5. doi: 10.1007/s12020-020-02573-1. Epub ahead of print. PMID: 33400175.

13: Liberini V, Huellner MW, Grimaldi S, Finessi M, Thuillier P, Muni A, Pellerito RE, Papotti MG, Piovesan A, Arvat E, Deandreis D.

The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future.



Diagnostics (Basel). 2020 Dec 12;10(12):1083. doi: 10.3390/diagnostics10121083. PMID: 33322819; PMCID: PMC7763988.

14: Nervo A, Ragni A, Retta F, Gallo M, Piovesan A, Liberini V, Gatti M, Ricardi U, Deandreis D, Arvat E.

Bone metastases from differentiated thyroid carcinoma: current knowledge and open issues.

J Endocrinol Invest. 2021 Mar;44(3):403-419. doi: 10.1007/s40618-020-01374-7. Epub 2020 Aug 3. PMID: 32743746; PMCID: PMC7878269.

15: Polverari G, Ceci F, Bertaglia V, Reale ML, Rampado O, Gallio E, Passera R, Liberini V, Scapoli P, Arena V, Racca M, Veltri A, Novello S, Deandreis D.

¹⁸F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival.

Cancers (Basel). 2020 May 5;12(5):1163. doi: 10.3390/cancers12051163. PMID: 32380754; PMCID: PMC7281558.

16: Deandreis D, Guarneri A, Ceci F, Lillaz B, Bartoncini S, Oderda M, Nicolotti DG, Pilati E, Passera R, Zitella A, Bellò M, Parise R, Carlevato R, Ricardi U, Gontero P.

⁶⁸Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC): a prospective single-centre study in patients eligible for salvage therapy. Eur J Nucl Med Mol Imaging.

2020 Nov;47(12):2804-2815. Doi: 10.1007/s00259-020-04809-8. Epub 2020 Apr 20. PMID: 32314028.

17: Pilati E, Nicolotti DG, Ceci F, Finessi M, Cerio I, Dionisi B, Zotta M, Bellò M, Deandreis D. ⁶⁸Ga-Prostate-Specific Membrane Antigen 11 PET/CT Detects Residual Glioblastoma After Radical Surgery in a Patient With Synchronous Recurrent Prostate Cancer: A Case Report.

Clin Nucl Med. 2020 Mar;45(3):e151-e153. doi: 10.1097/RLU.0000000000002884. PMID: 31876821.

18: Salaün PY, Abgral R, Malard O, Querellou-Lefranc S, Quere G, Wartski M, Coriat R, Hindie E, Taieb D, Tabarin A, Girard A, Grellier JF, Brenot-Rossi I, Groheux D, Rousseau C, Deandreis D, Alberini JL, Bodet-Milin C, Itti E, Casasnovas O, Kraeber-Bodere F, Moreau P, Philip A, Balleyguier C, Luciani A, Cachin F.

Good clinical practice recommendations for the use of PET/CT in oncology.

Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):28-50. Doi: 10.1007/s00259-019-04553-8. Epub 2019 Oct 21. PMID: 31637482.

19: Parasiliti-Caprino M, Lucatello B, Lopez C, Burrello J, Maletta F, Mistrangelo M, Migliore E, Tassone F, La Grotta A, Pia A, Reimondo G, Giordano R, Giraud G, Piovesan A, Ciccone G, Deandreis D, Limone P, Orlandi F, Borretta G, Volante M, Mulatero P, Papotti M, Aimaretti G, Terzolo M, Morino M, Pasini B, Veglio F, Ghigo E, Arvat E, Maccario M.

Predictors of recurrence of pheochromocytoma and paraganglioma: a multicenter study in Piedmont, Italy.

Hypertens Res. 2020 Jun;43(6):500-510. doi: 10.1038/s41440-019-0339-y. Epub 2019 Oct 4. PMID: 31586159.

20: Terroir M, Caramella C, Borget I, Bidault S, Dromain C, El Farsaoui K, Deandreis D, Grimaldi S, Lumbroso J, Berdelou A, Hadoux J, Hescot S, Hartl D, Baudin E, Schlumberger M, Leboulleux S.



F-18-Dopa Positron Emission Tomography/Computed Tomography Is More Sensitive Than Whole-Body Magnetic Resonance Imaging for the Localization of Persistent/Recurrent Disease of Medullary Thyroid Cancer Patients.

Thyroid. 2019 Oct;29(10):1457-1464. Doi: 10.1089/thy.2018.0351. PMID: 31530235.

21: Finessi M, Liberini V, Deandreis D.

Major limits of dosimetrically determined activities in advanced differentiated thyroid carcinoma.

Q J Nucl Med Mol Imaging. 2019 Sep;63(3):258-266. doi: 10.23736/S1824-4785.19.03211-4. Epub 2019 Sep 20. PMID: 31560183.

22: Terroir M, Grimaldi S, Hartl D, Leboulleux S, Deandreis D.

Parathyroid Glands Hyperplasias Mimicking Medullary Thyroid Carcinoma Metastatic Lymph Nodes on 18F-DOPA PET/CT.

Clin Nucl Med. 2019 Aug;44(8):e497-e498. Doi: 10.1097/RLU.0000000000002633. PMID: 31274634.

23: Finessi M, Bisi G, Deandreis D.

Hyperglycemia and 18F-FDG PET/CT, issues and problem solving: a literature review.

Acta Diabetol. 2020 Mar;57(3):253-262. doi: 10.1007/s00592-019-01385-8. Epub 2019 Jul 15. PMID: 31304560.

24: Morris MJ, Lorient Y, Sweeney CJ, Fizazi K, Ryan CJ, Shevrin DH, Antonarakis ES, Pandit-Taskar N, Deandreis D, Jacene HA, Vesselle H, Petrenciuc O, Lu C, Carrasquillo JA, Higano CS. Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. Eur J Cancer. 2019 Jun;114:107-116. Doi: 10.1016/j.ejca.2019.04.007. Epub 2019 May 11. PMID: 31082669; PMCID: PMC7474951.

25: Liberini V, Nicolotti DG, Maccario M, Finessi M, Deandreis D.

68Ga-DOTA-TOC PET/CT of von Hippel-Lindau Disease.

Clin Nucl Med. 2019 Feb;44(2):125-126. Doi: 10.1097/RLU.0000000000002395. PMID: 30516678.

26: Salaün PY, Abgral R, Malard O, Querellou-Lefranc S, Quere G, Wartski M, Coriat R, Hindie E, Taieb D, Tabarin A, Girard A, Grellier JF, Brenot-Rossi I, Groheux D, Rousseau C, Deandreis D, Alberini JL, Bodet-Milin C, Itti E, Casasnovas O, Kraeber-Bodere F, Moreau P, Philip A, Balleyguier C, Lucian A, Cachin F.

Actualisation des recommandations de bonne pratique clinique pour l'utilisation de la TEP en cancérologie [Update of the recommendations of good clinical practice for the use of PET in oncology]. Bull Cancer. 2019 Mar;106(3):262-274. French. doi: 10.1016/j.bulcan.2019.01.002. Epub 2019 Jan 23. PMID: 30683308.

27: Nicolotti DG, Finessi M, Guarneri A, Pilati E, Giunta F, Deandreis D.

Impact of functional imaging in prostate cancer: a clinical point of view.

Q J Nucl Med Mol Imaging. 2019 Mar;63(1):1-6. doi: 10.23736/S1824-4785.19.03160-1. Epub 2019 Jan 15. PMID: 30644307.

28: Schlumberger M, Leboulleux S, Catargi B, Deandreis D, Zerdoud S, Bardet S, Rusu D, Godbert Y, Buffet C, Schwartz C, Vera P, Morel O, Benisvy D, Bournaud C, Toubert ME, Kelly A, Benhamou E, Borget I.



Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial.

Lancet Diabetes Endocrinol. 2018 Aug;6(8):618-626. doi: 10.1016/S2213-8587(18)30113-X. Epub 2018 May 26. PMID: 29807824.

29: Grimaldi S, Young J, Kamenicky P, Hartl D, Terroir M, Leboulleux S, Berdelou A, Hadoux J, Hescot S, Remy H, Baudin E, Schlumberger M, Deandreis D.

Challenging pre-surgical localization of hyperfunctioning parathyroid glands in primary hyperparathyroidism: the added value of ¹⁸F-Fluorocholine PET/CT.

Eur J Nucl Med Mol Imaging. 2018 Sep;45(10):1772-1780. Doi: 10.1007/s00259-018-4018-z. Epub 2018 Apr 22. PMID: 29680989.

30: Finessi M, Nicolotti DG, Bisi G, Deandreis D.

Doxorubicin Effect on Myocardial Metabolism as a Prerequisite for Subsequent Development of Cardiac Toxicity: Are There Unsuspected Confounders?

J Nucl Med. 2018 Apr;59(4):713. doi: 10.2967/jnumed.117.205856. Epub 2018 Jan 11. PMID: 29326359.

31: Finessi M, Bellò M, Giunta FP, Veltri A, Deandreis D.

Interventional locoregional treatment and metabolic response: advantages of using PET/CT in the evaluation of response to treatment.

Q J Nucl Med Mol Imaging. 2018 Jun;62(2):165-184. doi: 10.23736/S1824-4785.17.03037-0. Epub 2017 Nov 22. PMID: 29166753.

32: Garbaccio V, Menga M, Mensa G, Passera R, Galati A, Codegone A, Finessi M, Pilati E, Deandreis D, Pellerito RE.

Impact of Radioguided Occult Lesion Localization (ROLL) in the management of cervical recurrences from differentiated thyroid cancer.

Q J Nucl Med Mol Imaging. 2017 Sep 20. doi: 10.23736/S1824-4785.17.03027-8. Epub ahead of print. PMID: 28933526.

33: Hadoux J, Terroir M, Leboulleux S, Deschamps F, Al Ghuzlan A, Hescot S, Tselikas L, Borget I, Caramella C, Déandréis D, Goere D, De Baere T, Schlumberger M, Baudin E. Interferon-alpha Treatment for Disease Control in Metastatic Pheochromocytoma/Paraganglioma Patients.

Horm Cancer. 2017 Dec;8(5-6):330-337. doi: 10.1007/s12672-017-0303-8. Epub 2017 Jul 26. PMID:28748315.

34: Deandreis D.

Reply: Fixed 3.7-GBq ¹³¹I Activity for Metastatic Thyroid Cancer Therapy Ignores Science and History.

J Nucl Med. 2017 Sep;58(9):1531. doi: 10.2967/jnumed.117.193185. Epub 2017 Apr 27. PMID: 28450565.

35: Lamartina L, Borget I, Mirghani H, Al Ghuzlan A, Berdelou A, Bidault F, Deandreis D, Baudin E, Travagli JP, Schlumberger M, Hartl DM, Leboulleux S.

Surgery for Neck Recurrence of Differentiated Thyroid Cancer: Outcomes and Risk Factors.



J Clin Endocrinol Metab. 2017 Mar 1;102(3):1020-1031. doi: 10.1210/jc.2016-3284. PMID: 28359102.

36: Sullivan I, Le Teuff G, Guigay J, Caramella C, Berdelou A, Leboulleux S, Déandréis D, Hadoux J, Ducreux M, Duvillard P, Adam J, Scoazec JY, Baudin E, Planchard D.

Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids.

Eur J Cancer. 2017 Apr;75:259-267. doi: 10.1016/j.ejca.2016.11.034. Epub 2017 Feb 27. PMID: 28242503.

37: Deandreis D, Schlumberger M, Tuttle RM.

Reply: Comparison of Empiric Versus Dosimetry-Guided Radioiodine Therapy: The Devil Is in the Details.

J Nucl Med. 2017 May;58(5):863-864. doi: 10.2967/jnumed.117.190496. Epub 2017 Feb 23. PMID: 28232612.

38: Dromain C, Déandréis D, Scoazec JY, Goere D, Ducreux M, Baudin E, Tselikas L.

Imaging of neuroendocrine tumors of the pancreas.

Diagn Interv Imaging. 2016 Dec;97(12):1241-1257. doi: 10.1016/j.diii.2016.07.012. Epub 2016 Nov 18. PMID:

27876341.

39: Terroir M, Borget I, Bidault F, Ricard M, Deschamps F, Hartl D, Tselikas L, Dercle L, Lumbroso J, Baudin E, Berdelou A, Deandreis D, Schlumberger M, Leboulleux S.

The intensity of 18FDG uptake does not predict tumor growth in patients with metastatic differentiated thyroid cancer.

Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):638-646. doi: 10.1007/s00259-016-3551-x. Epub 2016 Oct 29. PMID: 27796544.

40: Deandreis D, Rubino C, Tala H, Leboulleux S, Terroir M, Baudin E, Larson S, Fagin JA, Schlumberger M, Tuttle RM. Comparison of Empiric Versus Whole-Body/-Blood Clearance Dosimetry-Based Approach to Radioactive Iodine Treatment in Patients with Metastases from Differentiated Thyroid Cancer.

J Nucl Med. 2017 May;58(5):717-722. doi: 10.2967/jnumed.116.179606. Epub 2016 Oct 13. PMID: 27738010.

41: Hartl DM, Breuskin I, Mirghani H, Berdelou A, Déandréis D, Pottier E, Borget I, Schlumberger M, Leboulleux S.

Anatomic Variability of the Upper Mediastinal Lymph Node Level VII. World J Surg. 2016 Aug;40(8):1899-903. Doi: 10.1007/s00268-016-3505-2. PMID: 27075985.

42: Lamartina L, Deandreis D, Durante C, Filetti S.

ENDOCRINE TUMOURS: Imaging in the follow-up of differentiated thyroid cancer: current evidence and future perspectives for a risk-adapted approach.

Eur J Endocrinol. 2016 Nov;175(5):R185-202. doi: 10.1530/EJE-16-0088. Epub 2016 Jun 1. PMID: 27252484.

43: Dercle L, Deandreis D, Terroir M, Leboulleux S, Lumbroso J, Schlumberger M.



Evaluation of (124)I PET/CT and (124)I PET/MRI in the management of patients with differentiated thyroid cancer.

Eur J Nucl Med Mol Imaging. 2016 Jun;43(6):1006-10. doi: 10.1007/s00259-016-3334-4. PMID: 26928579.

44: Lamartina L, Ippolito S, Danis M, Bidault F, Borget I, Berdelou A, Al Ghuzlan A, Hartl D, Blanchard P, Terroir M, Deandreis D, Schlumberger M, Baudin E, Leboulleux S.

Antiangiogenic Tyrosine Kinase Inhibitors: Occurrence and Risk Factors of Hemoptysis in Refractory Thyroid Cancer.

J Clin Endocrinol Metab. 2016 Jul;101(7):2733-41. doi: 10.1210/jc.2015-4391. Epub 2016 Apr 15. PMID: 27082933.

45: Tacher V, Le Deley MC, Hollebécque A, Deschamps F, Vielh P, Hakime A, Ileana E, Abedi-Ardekani B, Charpy C, Massard C, Rosellini S, Gajda D, Celebic A, Ferté C, Ngo-Camus M, Gouissem S, Koubi-Pick V, Andre F, Vassal G, Deandreis D, Lacroix L, Soria JC, De Baère T. Factors associated with success of image-guided tumour biopsies: Results from a prospective molecular triage study (MOSCATO-01).

Eur J Cancer. 2016 May;59:79-89. doi: 10.1016/j.ejca.2016.02.006. Epub 2016 Mar 24. PMID: 27017289.

46: Deandreis D, Terroir M, Al Ghuzlan A, Berdelou A, Lacroix L, Bidault F, Troalen F, Hartl D, Lumbroso J, Baudin E, Schlumberger M, Leboulleux S.

¹⁸Fluorocholine PET/CT in parathyroid carcinoma: a new tool for disease staging?

Eur J Nucl Med Mol Imaging. 2015 Nov;42(12):1941-2. Doi: 10.1007/s00259-015-3130-6. Epub 2015 Aug 9. PMID: 26253272.

47: Borget I, Bonastre J, Catargi B, Déandréis D, Zerdoud S, Rusu D, Bardet S, Leenhardt L, Bastie D, Schwartz C, Vera P, Morel O, Benisvy D, Bournaud C, Bonichon F, Kelly A, Toubert ME, Leboulleux S, Journeau F, Benhamou E, Schlumberger M.

Quality of Life and Cost-Effectiveness Assessment of Radioiodine Ablation Strategies in Patients With Thyroid Cancer: Results From the Randomized Phase III ESTIMABL Trial. J Clin Oncol. 2015 Sep 10;33(26):2885-92. doi: 10.1200/JCO.2015.61.6722. Epub 2015 Aug 3. PMID: 26240230.

48: Baudin E; Endocrine Tumor Board of Gustave Roussy. Adrenocortical carcinoma.

Endocrinol Metab Clin North Am. 2015 Jun;44(2):411-34. doi:

10.1016/j.ecl.2015.03.001. Erratum in: Endocrinol Metab Clin North Am. 2015 Sep;44(3):xix. multiple investigator names added. PMID: 26038209.

49: Hartl DM, Leboulleux S, Velayoudom-Céphise FL, Mirghani H, Déandréis D, Schlumberger M. Management of retropharyngeal node metastases from thyroid carcinoma.

World J Surg. 2015 May;39(5):1274-81. doi: 10.1007/s00268-015-2947-2. PMID: 25585526.

50: Nascimento C, Borget I, Al Ghuzlan A, Deandreis D, Hartl D, Lumbroso J, Berdelou A, Lepoutre-Lussey C, Mirghani H, Baudin E, Schlumberger M, Leboulleux S.

Postoperative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography: an important imaging modality in patients with aggressive histology of differentiated thyroid cancer. Thyroid. 2015 Apr;25(4):437-44. doi: 10.1089/thy.2014.0320. Epub 2015 Mar 16. PMID: 25633259.



51: Hadoux J, Malka D, Planchard D, Scoazec JY, Caramella C, Guigay J, Boige V, Leboulleux S, Burtin P, Berdelou A, Lorient Y, Duvillard P, Chougnat CN, Déandréis D, Schlumberger M, Borget I, Ducreux M, Baudin E.

Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma.

Endocr Relat Cancer. 2015 Jun;22(3):289-98. doi: 10.1530/ERC-15-0075. Epub 2015 Mar 13. PMID: 25770151.

52: Bats AS, Frati A, Mathevet P, Orliaguet I, Querleu D, Zerdoud S, Leblanc E, Gauthier H, Uzan C, Deandreis D, Darai E, Kerrou K, Marret H, Lenain E, Froissart M, Lecuru F.

Contribution of lymphoscintigraphy to intraoperative sentinel lymph node detection in early cervical cancer: Analysis of the prospective multicenter SENTICOL cohort.

Gynecol Oncol. 2015 May;137(2):264-9. doi: 10.1016/j.ygyno.2015.02.018. Epub 2015 Feb 26. PMID: 25727652.

53: Deutsch E, Le Péchoux C, Faivre L, Rivera S, Tao Y, Pignon JP, Angokai M, Bahleda R, Deandreis D, Angevin E, Hennequin C, Besse B, Levy A, Soria JC.

Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer.

Ann Oncol. 2015 Jun;26(6):1223-1229. Doi: 10.1093/annonc/mdv105. Epub 2015 Feb 20. PMID: 25701455.

54: Lepoutre-Lussey C, Caramella C, Bidault F, Déandréis D, Berdelou A, Al Ghuzlan A, Hartl D, Borget I, Gimenez-Roqueplo AP, Dumont F, Deschamps F, Nascimento C, Lumbroso J, Guillaud Bataille M, Schlumberger M, Baudin E, Leboulleux S.

Screening in asymptomatic SDHx mutation carriers: added value of ¹⁸F-FDG PET/CT at initial diagnosis and 1-year follow-up.

Eur J Nucl Med Mol Imaging. 2015 May;42(6):868-76. doi: 10.1007/s00259-015-3003-z. Epub 2015 Feb 13. PMID: 25676472.

55: Levy A, Leboulleux S, Lepoutre-Lussey C, Baudin E, Ghuzlan AA, Hartl D, Deutsch E, Deandreis D, Lumbroso J, Tao Y, Schlumberger M, Blanchard P.

(¹⁸F)-fluorodeoxyglucose positron emission tomography to assess response after radiation therapy in anaplastic thyroid cancer.

Oral Oncol. 2015 Apr;51(4):370-5. doi: 10.1016/j.oraloncology.2014.12.014. Epub 2015 Jan 13. PMID: 25595614.

56: Bats AS, Frati A, Froissart M, Orliaguet I, Querleu D, Zerdoud S, Leblanc E, Gauthier H, Uzan C, Deandreis D, Darai E, Kerrou K, Marret H, Lenain E, Mathevet P, Lecuru F.

Feasibility and performance of lymphoscintigraphy in sentinel lymph node biopsy for early cervical cancer: results of the prospective multicenter SENTICOL study.

Ann Nucl Med. 2015 Jan;29(1):63-70. Doi: 10.1007/s12149-014-0910-1. Epub 2014 Nov 15. PMID: 25398308; PMCID: PMC4661194.

57: Lepoutre-Lussey C, Deandreis D, Leboulleux S, Schlumberger M.

Postoperative radioactive iodine administration for differentiated thyroid cancer patients.

Curr Opin Endocrinol Diabetes Obes. 2014 Oct;21(5):363-71. doi: 10.1097/MED.000000000000100. PMID: 25119656.



58: Hadoux J, Favier J, Scoazec JY, Leboulleux S, Al Ghuzlan A, Caramella C, Déandreis D, Borget I, Loriot C, Chougnat C, Letouzé E, Young J, Amar L, Bertherat J, Libé R, Dumont F, Deschamps F, Schlumberger M, Gimenez-Roqueplo AP, Baudin E.

SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.

Int J Cancer. 2014 Dec 1;135(11):2711-20. doi: 10.1002/ijc.28913. Epub 2014 May 5. PMID: 24752622.

59: Hartl DM, Zago S, Leboulleux S, Mirghani H, Déandreis D, Baudin E, Schlumberger M. Resection margins and prognosis in locally invasive thyroid cancer. Head Neck. 2014 Jul;36(7):1034-8. doi: 10.1002/hed.23406. Epub 2013 Oct 26. PMID: 23784860.

60: Nascimento C, Borget I, Troalen F, Al Ghuzlan A, Deandreis D, Hartl D, Lumbroso J, Chougnat CN, Baudin E, Schlumberger M, Leboulleux S.

Ultrasensitive serum thyroglobulin measurement is useful for the follow-up of patients treated with total thyroidectomy without radioactive iodine ablation.

Eur J Endocrinol. 2013 Oct 4;169(5):689-93. doi: 10.1530/EJE-13-0386. PMID: 23939918.

61: Leboulleux S, Borget I, Labro S, Bidault S, Vielh P, Hartl D, Dauchy S, Chougnat CN, Girard E, Azoulay S, Mirghani H, Berdelou A, Lumbroso J, Deandreis D, Baudin E, Schlumberger M, Laurent S. Frequency and intensity of pain related to thyroid nodule fine-needle aspiration cytology. Thyroid. 2013 Sep;23(9):1113-8. doi: 10.1089/thy.2012.0461. Epub 2013 Aug 27. PMID: 23384309.

62: Gouy S, Morice P, Narducci F, Uzan C, Martinez A, Rey A, Bentivegna E, Pautier P, Deandreis D, Querleu D, Haie-Meder C, Leblanc E.

Prospective multicenter study evaluating the survival of patients with locally advanced cervical cancer undergoing laparoscopic para-aortic lymphadenectomy before chemoradiotherapy in the era of positron emission tomography imaging.

J Clin Oncol. 2013 Aug 20;31(24):3026-33. doi: 10.1200/JCO.2012.47.3520. Epub 2013 Jul 15. PMID: 23857967.

63: Chougnat CN, Leboulleux S, Caramella C, Lumbroso J, Borget I, Déandreis D, Duvillard P, Elias D, de Baere T, Vélayoudom-Céphise FL, Guigay J, Ducreux M, Schlumberger M, Baudin E. Frequency and characterization of gastro-entero-pancreatic neuroendocrine tumor patients with high-grade of uptake at somatostatin receptor scintigraphy.

Endocr Relat Cancer. 2013 Mar

22;20(2):229-39. doi: 10.1530/ERC-12-0169. PMID: 23404855.

64: Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, Pentlow KS, Zanzonico PB, Haque S, Gavane S, Ghossein RA, Ricarte-Filho JC, Domínguez JM, Shen R, Tuttle RM, Larson SM, Fagin JA.

Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med. 2013 Feb 14;368(7):623-32. doi: 10.1056/NEJMoa1209288. PMID: 23406027; PMCID: PMC3615415.

65: Ayala-Ramirez M, Chougnat CN, Habra MA, Palmer JL, Leboulleux S, Cabanillas ME, Caramella C, Anderson P, Al Ghuzlan A, Waguespack SG, Deandreis D, Baudin E, Jimenez C. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas.



J Clin Endocrinol Metab. 2012 Nov;97(11):4040-50. doi: 10.1210/jc.2012-2356. Epub 2012 Sep 10. PMID: 22965939; PMCID: PMC3683800.

66: Leboulleux S, El Bez I, Borget I, Elleuch M, Déandreis D, Al Ghuzlan A, Chougnet C, Bidault F, Mirghani H, Lumbroso J, Hartl D, Baudin E, Schlumberger M.

Postradioiodine treatment whole-body scan in the era of 18-fluorodeoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levels.

Thyroid. 2012 Aug;22(8):832-8. Doi: 10.1089/thy.2012.0081. PMID: 22853728.

67: Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B, Bardet S, Leenhardt L, Bastie D, Schwartz C, Vera P, Morel O, Benisvy D, Bournaud C, Bonichon F, Dejoux C, Toubert ME, Leboulleux S, Ricard M, Benhamou E;

Tumeurs de la Thyroïde Refractaires Network for the Essai Stimulation Ablation

Equivalence Trial. Strategies of radioiodine ablation in patients with low-risk thyroid cancer.

N Engl J Med. 2012 May 3;366(18):1663-73. doi: 10.1056/NEJMoa1108586. PMID: 22551127.

68: Deandreis D, Al Ghuzlan A, Auperin A, Vielh P, Caillou B, Chami L, Lumbroso J, Travagli JP, Hartl D, Baudin E, Schlumberger M, Leboulleux S.

Is (18)F-fluorodeoxyglucose-PET/CT useful for the presurgical characterization of thyroid nodules with indeterminate fine needle aspiration cytology? Thyroid. 2012 Feb;22(2):165-72. doi: 10.1089/thy.2011.0255. Epub 2012 Jan 18. PMID: 22257371.

69: Baudin E, Leboulleux S, Al Ghuzlan A, Chougnet C, Young J, Deandreis D, Dumont F, Dechamps F, Caramella C, Chanson P, Lanoy E, Borget I, Schlumberger M.

Therapeutic management of advanced adrenocortical carcinoma: what do we know in 2011?

Horm Cancer. 2011 Dec;2(6):363-71. doi: 10.1007/s12672-011-0094-2. PMID: 22161625.

70: Deandreis D, Leboulleux S, Caramella C, Schlumberger M, Baudin E.

FDG PET in the management of patients with adrenal masses and adrenocortical carcinoma.

Horm Cancer. 2011 Dec;2(6):354-62. doi: 10.1007/s12672-011-0091-5. PMID: 22076881.

71: Mauclère-Denost S, Leboulleux S, Borget I, Paci A, Young J, Al Ghuzlan A, Deandreis D, Drouard L, Tabarin A, Chanson P, Schlumberger M, Baudin E.

High- dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up.

Eur J Endocrinol. 2012 Feb;166(2):261-8. doi: 10.1530/EJE-11-0557. Epub 2011 Nov 2.

PMID: 22048971.

72: Deandreis D, Lumbroso J, Al Ghuzlan A, Baudin E, Schlumberger M, Leboulleux S.

Abnormal pelvic uptake on post-therapeutic radioiodine (131I) whole-body scan. Eur J Nucl Med Mol Imaging. 2011 Oct;38(10):1957. doi:10.1007/s00259-011-1795-z. Epub 2011 Apr 2. PMID: 21461733.

73: Nascimento C, Borget I, Al Ghuzlan A, Deandreis D, Chami L, Travagli JP, Hartl D, Lumbroso J, Chougnet C, Lacroix L, Baudin E, Schlumberger M, Leboulleux S.

Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level. Endocr Relat Cancer. 2011 Mar 3;18(2):R29-40. doi: 10.1677/ERC-10-0292. PMID: 21183629.



74: Deandreis D, Al Ghuzlan A, Leboulleux S, Lacroix L, Garsi JP, Talbot M, Lumbroso J, Baudin E, Caillou B, Bidart JM, Schlumberger M. Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?

Endocr Relat Cancer. 2011 Jan 13;18(1):159-69. doi: 10.1677/ERC-10-0233. PMID: 21118976.

75: Abgral R, Leboulleux S, Déandreis D, Aupérin A, Lumbroso J, Dromain C, Duvillard P, Elias D, de Baere T, Guigay J, Ducreux M, Schlumberger M, Baudin E.

Performance of (18)fluorodeoxyglucose-positron emission tomography and somatostatin receptor scintigraphy for high Ki67 ($\geq 10\%$) well-differentiated endocrine carcinoma staging.

J Clin Endocrinol Metab. 2011 Mar;96(3):665-71. doi: 10.1210/jc.2010-2022. Epub 2010 Dec 30. PMID: 21193541.

76: Deandreis D, Leboulleux S, Dromain C, Auperin A, Coulot J, Lumbroso J, Deschamps F, Rao P, Schlumberger M, de Baère T. Role of FDG PET/CT and chest CT in the follow-up of lung lesions treated with radiofrequency ablation.

Radiology. 2011 Jan;258(1):270-6. doi: 10.1148/radiol.10092440. Epub 2010 Nov 2. PMID: 21045185.

77: Leboulleux S, Deandreis D, Escourrou C, Al Ghuzlan A, Bidault F, Aupérin A, Travagli JP, Lumbroso J, Schlumberger M, Baudin E.

Fluorodesoxyglucose uptake in the remaining adrenal glands during the follow-up of patients with adrenocortical carcinoma: do not consider it as malignancy.

Eur J Endocrinol. 2011 Jan;164(1):89-94. doi: 10.1530/EJE-10-0666. Epub 2010 Oct 4. PMID: 20921280.

78: Poisson T, Deandreis D, Leboulleux S, Bidault F, Bonniaud G, Baillet S, Aupérin A, Al Ghuzlan A, Travagli JP, Lumbroso J, Baudin E, Schlumberger M.

¹⁸F-fluorodeoxyglucose positron emission tomography and computed tomography in anaplastic thyroid cancer.

Eur J Nucl Med Mol Imaging. 2010 Dec;37(12):2277-85. doi: 10.1007/s00259-010-1570-6. Epub 2010 Aug 6. PMID: 20694463.

79: Leboulleux S, Deandreis D, Al Ghuzlan A, Aupérin A, Goéré D, Dromain C, Elias D, Caillou B, Travagli JP, De Baere T, Lumbroso J, Young J, Schlumberger M, Baudin E.

Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis? Eur J Endocrinol. 2010 Jun;162(6):1147-53. Doi: 10.1530/EJE-09-1096. Epub 2010 Mar 26. PMID: 20348273.

80: Penna D, Varetto T, Deandreis D, Castellano G, Bisi G.

Dual-phase F-18 FDG PET/CT scanning in the suspicion of relapse of ovarian neoplasia. Clin Nucl Med. 2009 Feb;34(2):111-3. doi: 10.1097/RLU.0b013e318192c3cc. PMID: 19352268.

81: Pelosi E, Pregno P, Penna D, Deandreis D, Chiappella A, Limerutti G, Vitolo U, Mancini M, Bisi G, Gallo E.

Role of whole-body [¹⁸F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma. Radiol Med. 2008 Jun;113(4):578-90. English, Italian. doi:



10.1007/s11547-008-0264-7. Epub 2008 Apr 14. PMID: 18414808.

82: Pelosi E, Penna D, Deandreis D, Chiappella A, Skanjeti A, Vitolo U, Bisi G.
FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.

Q J Nucl Med Mol Imaging. 2008 Mar;52(1):9-16. PMID: 18235420.

83: Pelosi E, Deandreis D. The role of 18F-fluoro-deoxy-glucose positron emission tomography (FDG-PET) in the management of patients with colorectal cancer. Eur J Surg Oncol. 2007 Feb;33(1):1-6. doi: 10.1016/j.ejso.2006.10.020. Epub 2006 Nov 27. PMID: 17126522.

84: Pelosi E, Pennone M, Deandreis D, Douroukas A, Mancini M, Bisi G.

Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site. Q J Nucl Med Mol Imaging. 2006 Mar;50(1):15-22. PMID: 16557200.

85: Saggiorato E, Arecco F, Mussa A, Sacerdote C, Rossetto R, Origlia C, Germano L, Deandreis D, Orlandi F; Piedmont Goiter Study Committee. Goiter prevalence and urinary iodine status in urban and rural/mountain areas of Piedmont region.

J Endocrinol Invest. 2006 Jan;29(1):67-73. doi: 10.1007/BF03349179. PMID: 16553036.

86: Saggiorato E, Mussa A, Sacerdote C, Rossetto R, Arecco F, Origlia C, Germano L, Deandreis D, Orlandi F; Piemonte Goiter Study Committee. Thyroid volume and urinary iodine excretion in the schoolchild population of a Northwestern Italian sub-Alp metropolitan area. J Endocrinol Invest. 2004 Jun;27(6):516-22. Doi: 10.1007/BF03347472. PMID: 15717647.

87: Saggiorato E, Aversa S, Deandreis D, Arecco F, Mussa A, Puligheddu B, Cappia S, Conticello S, Papotti M, Orlandi F.

Galectin-3: presurgical marker of thyroid follicular epithelial cell-derived carcinomas.

J Endocrinol Invest. 2004 Apr;27(4):311-7. doi: 10.1007/BF03351054. PMID: 15233548.

88: Osella G, Orlandi F, Caraci P, Ventura M, Deandreis D, Papotti M, Bongiovanni M, Angeli A, Terzolo M.

Acromegaly due to ectopic secretion of GHRH by bronchial carcinoid in a patient with empty sella. J Endocrinol Invest. 2003 Feb;26(2):163-9. doi: 10.1007/BF03345146. PMID: 12739745.

89: Papotti M, Volante M, Saggiorato E, Deandreis D, Veltri A, Orlandi F.

Role of galectin-3 immunodetection in the cytological diagnosis of thyroid cystic papillary carcinoma.

Eur J Endocrinol. 2002 Oct;147(4):515-21. doi:10.1530/eje.0.1470515. PMID: 12370115.